Budget impact analysis of PCSK9 inhibitors costs from a community payers’ perspective in Apulia, Italy

Natale Daniele Brunetti,1 Luisa De Gennaro,2 Lucia Tricarico,1 Pasquale Caldarola2

INTRODUCTION

The recent introduction of PCSK9 inhibitors (PCSK9i) in the treatment of hypercholesterolaemia, either in primary (familial hypercholesterolaemia (FH)) or secondary prevention after acute myocardial infarction (MI), radically innovated lipid-lowering therapy. The use of PCSK9i was safe and effective in the whole continuum of hypercholesterolaemia, from statin intolerants1 to lipid-lowering naive users,2 in addition or in alternative to ezetimibe,3 with either low-intensity and high-intensity statins,4 in FH.5 The switch to PCSK9i use is a more effective option than statin titration6 or switching between statins. Several clinical studies explored the efficacy of both evolocumab7 and alirocumab in lowering cholesterol levels down to blood concentrations unattainable with other drug approaches.8 9 Two recent randomised clinical studies finally demonstrated that such massive reduction of cholesterol levels correspond to lower rates of adverse cardiovascular (CV) events and mortality in subjects with CV disease.10 11 Despite clinical efficacy of PCSK9i in reducing CV events and cholesterol levels seems well established and endorsed by guidelines,12 the cost of PCSK9i still represents, however, a big matter of debate. Cost analyses conducted according to extremely rigorous criteria provided conflicting data on cost-effectiveness of this new class of drugs.13–15

However, such ‘rigorous’ approach to cost-effectiveness analysis does not always encompass the whole spectrum of cost burden of drugs and therapies. Studies such that from Poulsen et al show that, with a pharmacoeconomic analysis considering just the
cost of a new drug, it is often impossible to appreciate the whole possible positive impact following the introduction of a new treatment; that is the case of direct anticoagu-
lants in the prevention of thromboembolic complications of
atrial fibrillation. When, instead, also individual, munici-
pality and social costs are duly weighted, apparent in-
creased costs may turn into considerable savings.

We therefore sought to estimate possible impact of
PCSK9i therapy from a community payers’ perspective with a simple budget impact analysis (BIA) based on
new data coming from two randomised trials on PCSK9i,
recently published: the Further Cardiovascular Outcomes
Research with PCSK9 Inhibition in Subjects with Elevated
Risk (FOURIER) and the Evaluation of Cardiovascular
Outcomes After an Acute Coronary Syndrome During
Treatment With Alirocumab (ODYSSEY OUTCOMES)
study. According to common definitions, BIA should be
defined as an economic evaluation conducted according
to the budget holders’ perspective, with a short time
horizon (<3 years) and within a clearly specified setting,
where results are expressed as undiscounted cost differ-
ces between the new scenario (including the new tech-
nology/drug) and the current/reference scenario,
taking account of the potential trade-offs in healthcare
resources induced by the effectiveness of the new tech-
nology/drug, and easy to understand by budget holders;
the approach is radically different from a cost-effective-
ness analysis.

METHODS

The cost analysis was based on data from randomised
studies on clinical endpoints with evolocumab and aliro-
cumab. Clinical endpoints considered were death, MI, stroke, major adverse CV events (MACEs, death from CV causes, non-fatal MI, unstable angina requiring hospitalisation, an ischaemia-driven coronary revascularisation procedure or non-fatal ischaemic stroke), or the composite endpoint death, MI, stroke for the ODYSSEY OUTCOMES study, MI, stroke, MACE (CV death, MI, stroke, hospitalisation for unstable angina, coronary revascularisation), the composite endpoint CV death, MI, stroke for the FOURIER study. Data from two randomised
studies were used to estimate absolute risk reduction and
consequent number needed to treat for each drug and
outcome. The follow-up considered was 34 months for
the ODYSSEY OUTCOMES study and 26 months for the
FOURIER.

The analysis focused on Apulia region, South-Eastern
Italy (4,063,888 inhabitants (figure 1)). The cost of drugs is
locally paid by Regional Public Health Care System for
all citizens according to official drug indications when endorsed by local Healthcare Authority. The considered
cost for 1-year treatment was currently €4,500, according
to present bargain between pharmaceutical companies and
Apulia Public Health Care System. The cost per saved event (annual cost of therapy per number needed to treat) was indexed per 1 year to compare results from studies with different follow-up. Costs per CV event saved were calculated and indexed per Apulia inhabitants to allow a comprehensive evalua-
tion of community costs as in prior analysis. Data were also presented as individual (per Apulia’s inhabitant) cost per saved event and events saved for individual €1 expense per 1 year.

RESULTS

On the base of actual cost in Apulia sustained by Regional
Public Health Care System for PCSK9i, Apulia’s popula-
tion, clinical efficacy data from randomised clinical
studies, different follow-up durations, absolute risk
reduction, number needed to treat, esteemed costs per
CV event avoided thanks to alirocumab therapy were
2.1 millions for one death, 1.3 for one MI, 3.2 for one
stroke, 0.7 for one MACE (death from CV causes, non-
fatal MI, unstable angina requiring hospitalisation, an
ischaemia-driven coronary revascularisation procedure or non-fatal ischaemic stroke) and 0.8 for one
major event (CV death, MI, stroke) (table 1).

However, when costs per saved adverse event were
indexed according to Apulia’s population (and an ideal
taxpayers’ community), the individual annual cost per
CV event avoided thanks to alirocumab therapy was
0.51 for one all-cause death, 0.31 for one MI, 0.78 for one stroke, 0.16 for one MACE and 0.20 for one
major event (CV death, MI, stroke).

With €1 annually spent per Apulia’s inhabitant, 2
all-cause deaths, 3.2 MIs, 1.3 strokes and 6.1 MACEs
could be avoided.

When considering subjects in secondary prevention
after MI and baseline cholesterol levels >100 mg/dL,
the annual cost per Apulia’s inhabitant for one all-cause
death avoided thanks to alirocumab therapy was more
than halved to €0.19 and the cost for a saved MACE was
€0.09. With €1 annually spent per Apulia’s inhabitant,
10.9 MACEs and 5.3 all-cause deaths could be saved.

In an ideal scenario of treatment with evolocumab,
the individual annual cost per CV event avoided thanks
to PCSK9i therapy was €0.13 for one MI, €0.12 for one
MACE (CV death, MI, stroke, hospitalisation for unstable

---

Figure 1  Apulia, South-Eastern Italy, 4 million inhabitants.
Table 1  Overall and per inhabitant costs per saved cardiovascular events according to randomised trials and drug costs (Apulia region, South-Eastern Italy)

| Endpoint                     | ARR | NNT | Cost per saved event per year, € (millions) | Cost per saved event per year per inhabitant, € | Saved events with €1 per inhabitant per year |
|------------------------------|-----|-----|---------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| ODYSEY OUTCOMES              |     |     |                                             |                                               |                                               |
| All-cause death              | 0.6 | 163 | 2.1                                        | 0.51                                          | 2.0                                           |
| MI                           | 1   | 100 | 1.3                                        | 0.31                                          | 3.2                                           |
| Stroke                       | 0.4 | 250 | 3.2                                        | 0.78                                          | 1.3                                           |
| MACE*                        | 1.9 | 53  | 0.7                                        | 0.16                                          | 6.1                                           |
| Death, MI, stroke            | 1.6 | 64  | 0.8                                        | 0.20                                          | 5.0                                           |
| LDL baseline levels >100 mg/dL|     |     |                                             |                                               |                                               |
| Death, MI, stroke            | 3.4 | 29  | 0.4                                        | 0.09                                          | 10.9                                          |
| All-cause death              | 1.7 | 60  | 0.8                                        | 0.19                                          | 5.3                                           |
| FOURIER                      |     |     |                                             |                                               |                                               |
| MI                           | 1.9 | 53  | 0.5                                        | 0.13                                          | 7.9                                           |
| Stroke                       | 0.4 | 250 | 2.4                                        | 0.60                                          | 1.7                                           |
| MACE†                        | 2   | 50  | 0.5                                        | 0.12                                          | 8.3                                           |
| CV death, MI, stroke         | 2   | 50  | 0.5                                        | 0.12                                          | 8.3                                           |
| Multivessel coronary disease |     |     |                                             |                                               |                                               |
| MACE†                        | 3.6 | 28  | 0.3                                        | 0.07                                          | 15.0                                          |
| CV death, MI, stroke         | 3.4 | 29  | 0.3                                        | 0.07                                          | 14.2                                          |

*Death from CV causes, non-fatal MI, unstable angina requiring hospitalisation, an ischaemia-driven coronary revascularisation procedure or non-fatal ischaemic stroke. †Cardiovascular death, MI, stroke, hospitalisation for unstable angina, coronary revascularisation.

ARR, absolute risk reduction; CV, cardiovascular; FOURIER, Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; LDL, low-density lipoprotein; MACE, major adverse CV event; MI, myocardial infarction; NNT, number needed to treat; ODYSEY OUTCOMES, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab.

Table: Overall and per inhabitant costs per saved cardiovascular events according to randomised trials and drug costs (Apulia region, South-Eastern Italy)

| Endpoint                     | ARR | NNT | Cost per saved event per year, € (millions) | Cost per saved event per year per inhabitant, € | Saved events with €1 per inhabitant per year |
|------------------------------|-----|-----|---------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| ODYSEY OUTCOMES              |     |     |                                             |                                               |                                               |
| All-cause death              | 0.6 | 163 | 2.1                                        | 0.51                                          | 2.0                                           |
| MI                           | 1   | 100 | 1.3                                        | 0.31                                          | 3.2                                           |
| Stroke                       | 0.4 | 250 | 3.2                                        | 0.78                                          | 1.3                                           |
| MACE*                        | 1.9 | 53  | 0.7                                        | 0.16                                          | 6.1                                           |
| Death, MI, stroke            | 1.6 | 64  | 0.8                                        | 0.20                                          | 5.0                                           |
| LDL baseline levels >100 mg/dL|     |     |                                             |                                               |                                               |
| Death, MI, stroke            | 3.4 | 29  | 0.4                                        | 0.09                                          | 10.9                                          |
| All-cause death              | 1.7 | 60  | 0.8                                        | 0.19                                          | 5.3                                           |
| FOURIER                      |     |     |                                             |                                               |                                               |
| MI                           | 1.9 | 53  | 0.5                                        | 0.13                                          | 7.9                                           |
| Stroke                       | 0.4 | 250 | 2.4                                        | 0.60                                          | 1.7                                           |
| MACE†                        | 2   | 50  | 0.5                                        | 0.12                                          | 8.3                                           |
| CV death, MI, stroke         | 2   | 50  | 0.5                                        | 0.12                                          | 8.3                                           |
| Multivessel coronary disease |     |     |                                             |                                               |                                               |
| MACE†                        | 3.6 | 28  | 0.3                                        | 0.07                                          | 15.0                                          |
| CV death, MI, stroke         | 3.4 | 29  | 0.3                                        | 0.07                                          | 14.2                                          |

*Death from CV causes, non-fatal MI, unstable angina requiring hospitalisation, an ischaemia-driven coronary revascularisation procedure or non-fatal ischaemic stroke. †Cardiovascular death, MI, stroke, hospitalisation for unstable angina, coronary revascularisation.

ARR, absolute risk reduction; CV, cardiovascular; FOURIER, Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; LDL, low-density lipoprotein; MACE, major adverse CV event; MI, myocardial infarction; NNT, number needed to treat; ODYSEY OUTCOMES, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab.

with €1 annually spent per Apulia’s inhabitant 7.9 MIs, 1.7 strokes and 8.3 MACEs could be avoided.

When considering subjects with multivessel coronary disease, the annual cost per Apulia’s inhabitant for one MACE avoided thanks to evolocumab therapy was near halved to €0.07. With just €1 annually spent per Apulia’s inhabitant, 15 MACEs could be saved.

With €1 annually spent per Apulia’s inhabitant 7.9 MIs, 1.7 strokes and 8.3 MACEs could be avoided.

When considering subjects with multivessel coronary disease, the annual cost per Apulia’s inhabitant for one MACE avoided thanks to evolocumab therapy was near halved to €0.07. With just €1 annually spent per Apulia’s inhabitant, 15 MACEs could be saved.

Costs per saved event and events saved with €1 both indexed per 1 million taxpayers are given in figure 2 for an easy application of this BIA to other taxpayers’ contexts.

DISCUSSION

In this analysis we esteem for the first time possible impact of therapy with PCSK9i from a taxpayers’ community perspective, simulating clinical data from two randomised studies in a public healthcare system scenario. Results show that apparently high costs per event saved, when considered from a wider perspective of a taxpayers’ community, may turn into very small individual annual costs.

This approach, although not exactly ‘rigorous’ from a pharmacoeconomic point of view, is not completely inappropriate and disreputable. Besides cost-effectiveness analyses, BIA may more accurately assess real economic impact of new therapies and drugs on reimbursing institutions, public healthcare system administrators and taxpayers. In another drug and disease context, direct anticoagulant for the prevention of thromboembolic complications of atrial fibrillation showed that increased drug costs may be associated with lower social costs, when all the components influencing the social burden of illnesses are duly considered. Higher drug costs may therefore be followed by lower social and community costs, when more expensive treatments significantly reduce adverse events and mortality rates. A health economic assessment based on a BIA rather than a cost-effectiveness analysis may be essential for a careful resource allocation when healthcare budgets should bear the burden of cuts as nowadays in several countries. As for Apulia region, annual rates of CV death is 29.7/10000 inhabitants and 7.62/10000 inhabitants for ischaemic heart disease. Given an annual incidence of acute MI of about 8000 cases, a 30% of patients with low-density lipoprotein (LDL) levels>100 mg/dL after acute MI
Despite optimal therapy with statins, a 10% mortality rates at 1 year and a presumable number of reinfarctions, at least 1000–1500 patients could be hypothetically eligible for PCSK9i in Apulia every year just in secondary prevention. LDL levels >100 mg/dL despite optimal treatment with statins and ezetimibe are currently mandatory for PCSK9i reimbursement in Apulia.

The vast majority of cost analyses available on PCSK9i, however, are still represented by cost-effectiveness evaluations based on non-clinical studies with laboratory endpoints; the recent publication of the FOURIER and the ODYSSEY OUTCOMES studies, targeted on hard clinical endpoints, allowed a series of cost-effectiveness analyses which showed contrasting conclusion on PCSK9i.

In a cost analysis from Fonarow et al, at its current (when the study was held) list price of US$14 523, the addition of evolocumab to standard background therapy in patients with atherosclerotic CV disease exceeded generally accepted cost-effectiveness thresholds. To achieve an incremental cost-effectiveness ratio (ICER) of US$150 000 per quality-adjusted life year (QALY), the annual net price would need to be substantially lower (US$9669 for US clinical practice and US$6780 for trial participants), or a higher-risk population would need to be treated.13

Another updated analysis on the FOURIER data concluded that only reducing annual drug costs of evolocumab by 71% (to ≤US$4215) would be needed for
PCSK9i to be cost-effective at a threshold of US$100 000/QAL.\textsuperscript{25}

Fewer data are available when a BIA is chosen rather than cost-effectiveness analysis. In an BIA analysis from Spain, with an average annual cost of patients receiving evolocumab of €11 134.78 and €393.83 for standard treatment (statins plus ezetimibe), the ICER was >€60 000 per avoided CV event for both assessed outcomes (first: CV death, MI, stroke and hospitalisation due to unstable angina or coronary revascularisation; second: includes the first three events). Authors claim that treatment with evolocumab is inefficient for patients suitable to receive this drug in the Spanish National Health System.\textsuperscript{26}

According to a recent study presented at 2018 American Heart Association congress, however, alirocumab was cost-effective at US$6319 at a threshold of US$100 000 per QALY, but in patients with baseline LDL cholesterol of 100 mg/dL or greater, alirocumab was cost-effective at an even higher price of US$13 400 a year at this willingness-to-pay threshold.\textsuperscript{27}

Interestingly, the actual cost per 1-year therapy with PCSK9i is in Apulia well below such esteemed cost-effectiveness threshold.

Surely, lower costs of PCSK9i would further improve the cost-effectiveness profile of this new class of drugs, but their positive impact in terms of reduced incidence of CV events is unquestioned. The identification of high-risk subgroups of patients, in the presence of clear evidence of more convenient cost-effectiveness ratios in such class of patients, may further contribute to reduce total and individual cost sustained by private and public community payers.

**CONCLUSIONS**

When considered from a large taxpayers’ community perspective, relevant costs per CV event saved with PCSK9i may turn into very small individual costs per year. The further selection of high risk subgroups may further reduce individual costs.

**Limitations**

Costs per event saved are indexed for Apulia population; larger populations and taxpayers’ communities may further reduce the individual costs per saved event. Lower cost of drugs may further reduce total and individual costs.

The analysis assumes for simpler calculations, a constant incidence of events during follow-up and a ‘global’ population of taxpayers; results may be therefore reassessed and corrected according to the ratio of taxpayers over local population (50% taxpayers, double costs …).

**Contributors**
PC conducted the study, LT gathered data, NDB analysed data, LDG and NDB wrote the paper, and PC and NDB supervised the study.

**Funding**
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**
NDB received honoraria from Sanofi as consultant.

**Patient consent for publication**
Not required.

---

**REFERENCES**

1. Nissen SE, Stoess E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. *JAMA* 2016;315:1580–90.

2. Køren MJ, Lundt P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. *J Am Coll Cardiol* 2014;63:2531–40.

3. Cannon CP, Carliou B, Blom D, et al. Efficacy and safety of alirocumab in postcardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the odyssey Combo II randomized controlled trial. *Eur Heart J* 2015;36:1186–94.

4. Giugliano RP, Keech A, Murphy SA, et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a Maximal-Potency statin in a randomized clinical trial. *JAMA Cardiol* 2017;2:1385–91.

5. Kastelein JIP, Ginsberg HN, Langsted G, et al. Odyssey FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. *Eur Heart J* 2015;36;ehv370–3.

6. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to resvasatrin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the odyssey options II randomized trial. *Atherosclerosis* 2016;244:138–46.

7. Markham A. Evolocumab: first global approval. *Drugs* 2015;75:1567–73.

8. Karatasakis A, Danek BA, Karacsonyi J, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. *J Am Heart Assoc* 2017;6. doi:10.1161/JAHA.117.006910.

9. Robinson JO, Nedergaard BS, Rogers NW, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. *JAMA* 2014;311:1870–82.

10. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017;376:1713–22.

11. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med* 2018;379:2097–107.

12. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ABC/ACP/NASPE/PCNA guideline on the management of blood cholesterol: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. *J Am Coll Cardiol* 2019;73:3168–209.

13. Fonarow GC, Keech AC, Pedersen TR, et al. Cost-Effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. *JAMA Cardiol* 2017;2:1069–78.

14. Gandara SR, Villa G, Fonarow GC, et al. Cost-Effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. *Clin Cardiol* 2016;39:313–20.

15. Virani SS, Akeroyd JM, Nambl V, et al. Applicability and cost implications for proprotein convertase subtilisin/kexin type 9 inhibitors based on the odyssey outcomes trial. *Circulation* 2019;139:410–2.

16. Poulsen PB, Johnsen SP, Hansen ML, et al. Setting priorities in the health care sector - the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark. *Clinicoecon Outcomes Res* 2017;9:617–27.

17. Garattini L, van de Vroen K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. *Eur J Health Econ* 2011;12:499–502.

18. Apulia. Available: https://en.wikipedia.org/wiki/Apulia [Accessed 8 Dec 2018].
19. Brunetti ND, De Gennaro L, Caldariola P, et al. Direct oral anticoagulants for the prevention of thromboembolic complications of atrial fibrillation: the more you pay, the less you spend? *Int J Cardiol* 2017;241:238–40.

20. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease. *Circulation* 2018;138:756–66.

21. I.Stat. Initial cause of death - European Short List, 2019. Available: http://dati.istat.it/Index.aspx?DataSetCode=DCIS_CMORTE1_RES# [Accessed 24 Jun 2019].

22. Concept paper sul Progetto inibitori di PCSK9: accesso E sostenibilit. SPS N. 1, 2019Available: https://issuu.com/pensiero/docs/supp_ps_1-2019_web [Accessed 24 Jun 2019].

23. De Luca L, Temporelli PL, Lucci D, et al. Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: insights from the start study. *PLoS One* 2018;13:e0199770.

24. Ministry of Health, National Agency for Regional Health Services. Infarto Miocardico Acuto: mortalità un anno, 2019. Available: https://pne.agenas.it/PNead17/risultati/tipo1/intr_struasi1_HC.php?id=88&tipo=1&area=1 [Accessed 25 Jun 2019].

25. Kazi DS, Penko J, Coxson PG, et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the Fourier trial. *JAMA* 2017;318:748–50.

26. Olyr de Labry Lima A, Gimeno Ballester V, Sierra Sánchez JF, et al. Cost-Effectiveness and budget impact of treatment with evolocumab versus statins and ezetimibe for hypercholesterolemia in Spain. *Rev Esp Cardiol* 2018;71:1027–35.

27. 19490 - Cost-effectiveness of alirocumab based on evidence from a large multinational outcome trial: The odyssey outcomes economics study. Available: http://www.abstractsonline.com/pp8/#!/4682/presentation/59408